Beam Therapeutics
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines aimed at treating serious diseases. The company utilizes its innovative base editing technology, which allows for targeted modifications of single bases in the genome without causing double-stranded breaks in DNA. This approach aims to create a new class of genetic therapies offering potential lifelong cures. Beam's pipeline includes therapies for conditions such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and various other disorders, including alpha-1 antitrypsin deficiency and certain neurological conditions. The company also has a research and clinical collaboration agreement with Magenta Therapeutics, further enhancing its development capabilities.
Guide Therapeutics, Inc., through its proprietary screening platform, discovers and develops nanoparticles to deliver therapeutics for gene therapy. The company assigns a barcode to, injects, and tracks nanoparticles. It attaches a reporter molecule to each nanoparticle that reports if the drug has been delivered into the cell and the drug works. Guide Therapeutics, Inc. was incorporated in 2018 and is based in Tucker, Georgia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.